Amivantamab-vmjw receives fast approval from the FDA for metastatic non-small cell lung cancer

Share This Post

August 2021: The FDA granted amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.), a bispecific antibody directed against epidermal growth factor (EGF) and MET receptors, accelerated approval for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test.

The Guardant360® CDx (Guardant Health, Inc.) has also been approved by the FDA as a companion diagnostic for amivantamab-vmjw.

CHRYSALIS, a multicenter, non-randomized, open label, multicohort clinical trial (NCT02609776) that included patients with locally advanced or metastatic NSCLC who had EGFR exon 20 insertion mutations, was used to gain approval. Efficacy was assessed in 81 patients with advanced NSCLC who had EGFR exon 20 insertion mutations and had progressed after platinum-based treatment. Amivantamab-vmjw was given to patients once a week for four weeks, then every two weeks until disease progression or unacceptable toxicity.

Overall response rate (ORR) according to RECIST 1.1 as assessed by blinded independent central review (BICR) and response duration were the key efficacy outcome measures. With a median response time of 11.1 months, the ORR was 40% (95 percent CI: 29 percent, 51 percent) (95 percent CI: 6.9, not evaluable).

Rash, infusion-related responses, paronychia, musculoskeletal pain, dyspnea, nausea, exhaustion, edoema, stomatitis, cough, constipation, and vomiting were the most prevalent side events (20%).

The recommended dose of amivantamab-vmjw is 1050 mg for patients with a baseline body weight of less than 80 kg and 1400 mg for those with a baseline body weight of more than 80 kg, given weekly for four weeks and then every two weeks until disease progression or unacceptable toxicity occurs.

 

Reference: 

https://www.fda.gov/

Check details here.

Take second opinion on lung cancer treatment


Send Details

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy